TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Asthma symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative oxycodone consumption per kilogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risky driving behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trovafloxacin tissue concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of technical success of drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spread of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of respiratory manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of radiographic infiltrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of home visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: performance time for GWMFT task (lift washcloth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grip termination time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of severe PTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of participation in self-help groups
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Abstinence rate
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Time until appropriate treatment was ordered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of platelet aggregation from 4 h to 24 h (IPA4-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sinus rhythm maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: procedural AF termination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drooling control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at scheduled appointments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: reduction of inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of noninflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned extubation incidence
Endpoint domain: Adverse events/effects
Primary endpoint: average fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: worse fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Overall renal response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serious infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease of TEWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fatigue perception
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Satiety scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Likelihood of using deception
Endpoint domain: Adverse events/effects
Primary endpoint: GIRAUC24-30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: survival for >7 days after study completion
Endpoint domain: Mortality/survival
Primary endpoint: discontinuation due to drug‐related adverse events (grades 3‐4)
Endpoint domain: Adverse events/effects
Primary endpoint: resolution of fever during neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total invasive respiratory support rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative pain scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recovery of liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of blood lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mental Component Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Social Function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Plasma aripiprazole concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Common adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Oral health knowledge (OHK)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral health behavior (OHB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral hygiene status (OHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime sleepiness reduction
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: English word recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Seizures during placebo phase
Endpoint domain: Adverse events/effects
Primary endpoint: weight SD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M6 physical activity improvements
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: visuospatial short-term memory (STM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: working memory (WM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: inhibitory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean chromium concentration in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean cobalt concentration in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cause-specific mortality related to COPD
Endpoint domain: Mortality/survival
Primary endpoint: AVF thrombosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 4 year cumulative actuarial survival
Endpoint domain: Mortality/survival
Primary endpoint: Hemodynamic effects (PAP and BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agreement for nodal staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement for extra-nodal staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity for staging nodal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of thalidomide
Endpoint domain: Adverse events/effects
Primary endpoint: glycaemic status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grade 3/4 skin toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure at peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: B/ST ratio for the skull
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ACR improvement criteria fulfillment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of YBOCS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inter-observer agreement for identification of angiographic abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in RBC transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean decrease in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % time spent under pH 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cumulative arrhythmic mortality at 42 months
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative nonarrhythmic cardiac mortality at 42 months
Endpoint domain: Mortality/survival
Primary endpoint: mean sweat chloride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: forced expiratory volume in 1s (percent predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: self-management
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Eating Behavior Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of Information for Dietary Decision Making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Calorie Restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal ADP-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Central adiposity defined as waist circumference 80 cm or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positivity rate of HUTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Syncope occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: maximum enhancement of the aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of the arterial phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased risk of Pneumocystis carinii pneumonia (PCP)
Endpoint domain: Mortality/survival
Primary endpoint: percentage of metaphase II oocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: fertilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: embryo quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: diastolic blood pressure iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: systolic blood pressure iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma nitrite response iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median crying time following IV cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delineation of lesion margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating IgE against HDM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Th2-cytokine production (IL-4, IL-5, IL-13)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: endothelium-dependent flow-mediated vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: curative effect in treating syndromes of wind‐fire and phlegm stagnation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: management of hemorrhagic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: treatment of left‐side cerebral injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean serum potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of dental anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CFA (Cystic Fibrosis Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and tolerability of the preparations
Endpoint domain: Adverse events/effects
Primary endpoint: maximum increase in insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incremental area under the curve (iAUC) for insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: C‐peptide/insulin quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Allergen-induced skin wheal responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma levels of SP, VIP and NGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in depth and length of glabellar frown lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early recurrence of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left superior PV and right superior PV contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of incisional hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 24-month weight loss or less weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life indices
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SGRQ total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total serum bilirubin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of body weight lost at month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight maintenance at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma zinc levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythrocyte zinc levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intraocular pressure (IOP) elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal thickness increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal optical density change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival to hospital discharge with an mRS score of 0 to 3
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative opioid requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum β‐endorphin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CSA at the level of the C6 root
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean CSA at the middle trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean CSA at the medial cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CI-AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 30-day incidence of adverse cardiovascular and renal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of death or nonfatal myocardial infarction at 6 month follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline on the MADRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour urine pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Net acid excretion (NAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of NAE excreted as ammonium (NH4+/NAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk for clinical worsening event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of new postoperative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: requirement for internal defibrillation and temporary epicardial pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increased platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improved coagulation indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cost of recruitment activities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum S-COMT inhibition (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative false positioning of the intraocular lens
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment success for impetigo with and without scabies coinfection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects considering vaccination if recommended by a doctor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: clinically meaningful reductions in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Financial worries during and after ICU stay
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: global rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedural rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death from vascular causes, myocardial infarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: MAP (Mean Arterial Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central venous oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luminal concentrations of L-lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Optic disc size estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of interruptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedural failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical errors per 100 medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to 36 weeks of postmenstrual age without bronchopulmonary dysplasia
Endpoint domain: Mortality/survival
Primary endpoint: Number of women screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Healing time prior to implant placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leading cause of death
Endpoint domain: Mortality/survival
Primary endpoint: leading risk factor for death
Endpoint domain: Mortality/survival
Primary endpoint: leading risk factor for disability-adjusted life-years lost
Endpoint domain: Mortality/survival
Primary endpoint: Mean scores on the knot-tying checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tightness of RHAP knots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in tying RHAP knots
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Epworth sleepiness scale (ESS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Treatment adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of missed injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consideration of obstetrics and gynecology as a career
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Sexual functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of MRI for detecting TAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence and type of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical repair initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: GAF scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life